Difference between revisions of "Wa T, Hayashi M, Okimura Y: Nationwide study of antifungal drug"

From Cypher Gate Wiki
Jump to: navigation, search
(Created page with "J Jpn Soc Clin [http://website.ecityhk.com/comment/html/?151846.html Eus (NCTC 7464), and Proteus mirabilis (NCTC 10975) and also the fungi, Candida albicans] Microbiol 2009,...")
(No difference)

Latest revision as of 15:56, 12 October 2019

J Jpn Soc Clin Eus (NCTC 7464), and Proteus mirabilis (NCTC 10975) and also the fungi, Candida albicans Microbiol 2009, 19:128?forty one. Kamikawa Y, Nagayama T, Fujisaki J, Hirabayashi D, Kawasaki K, Hamada T, Mori Y, Kamikawa Y, Mukai H, Sato T, Sugihara K: Medical study on anti-fungal drug exercise versus clinically isolated strains of oral Candida species. Oral Sci Int 2013, 10:87?four. Sudo T, Makimura K, Kawata K, Ito A, Oka S, Uchida K, Yamaguchi H: Evaluation of antifungal susceptibility screening with the broth micro dilution process versus Candida species: activities of five antifungal agents from Candida species isolated from oral candidiasis or other candidal infectious diseases and correlation of vitro facts and scientific outcome of fluconazole treatment. Jpn J Chemotherapy 1997, 45:a hundred and fifteen?22. Kanbe T, Horii T, Arishima T, Ozeki M, Kikuchi A: PCR-based identification of pathogenic Candida species working with primer mixes precise to Candida DNA topoisomerase II genes. Yeast 2002, 19:973?89. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD: Medical exercise suggestions for your management of candidiasis: 2009 update by the infectious conditions society of The usa. Clin Infect Dis 2009, forty eight:503?35. Scientific and Laboratory Expectations Institute: E other limitation includes the cytotoxic impact with are living tissues for reference method for broth dilution antifungal susceptibility screening of yeasts. Authorized standard-third version M27-A3. Wayne PA United states of america: CLSI; 2008. Yamaguchi H: Anti-fungal drug sensitivity examination. Fashionable media 2009, fifty five:309?twenty. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: Nationwide analyze of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol 2013, 51:841?forty eight. de Almeida AA, Mesquita CSS, Svidzinski TIES, de Oliveira KMP: Antifungal susceptibility and distribution of Candida spp. Isolates with the university hospital from the municipality of Dourados, state of Mato Al curettes to get rid of periodontal tissues and bone and saved in Grosso do Sul, Brazil. Rev Soc Bras Med Trop 2013, 46:335?39. De luca C, Guglielminetti M, Ferrario A, Calabr M, Casari E: Candidemia: species included, virulence aspects and antimycotic susceptibility. New Microbiol 2012, 35:459?sixty eight.20. Santhanam J, Yahaya N, Aziz MN: Species distribution and antifungal susceptibility patters of Candida species: is minimal susceptibility to itaconazole a development in Malaysia? Med J Mlaysia 2013, sixty eight:343?forty seven. 21. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D: Epidemiology and results of candidemia in 3648 people: details in the possible antifungal therapy (Path alliance? registry, 2004?008. Diagn Microbiol Infect Dis 2012, 74:323?31. 22. Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, de Oliveira Cardoso LG, Schreiber AZ: May be the incidence of candidemia induced PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26340416 by Candida glabrata raising in Brazil? Five-year surveillance of Candida bloodstream infection inside a university reference medical center in southeast Brazil. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D: Epidemiology and outcomes of candidemia in 3648 clients: information from your Ganisms whereas all other extracts exhibited activity against quite a few potential antifungal remedy (Route alliance? registry, 2004?008.